Telemedicine benefits

Article

Using a telemedicine system to assist ophthalmologists in developing countries with the diagnosis and management of various ophthalmic conditions can be successful.

Using a telemedicine system to assist ophthalmologists in developing countries with the diagnosis and management of various ophthalmic conditions can be successful, according to a study published in the January issue of Clinical Ophthalmology.

Itay BenZion from Doar Na Hof, Ha Carmel, Israel and Eugene Helveston from the Indiana School of Medicine, USA and ORBIS International compared diagnosis and treatment plans of local ophthalmologists, via ORBIS' telemedicine system Cyber-Sight, to those of ORBIS expert mentors.

Records of referrals of patients via Cyber-Sight to mentors with a diagnosis of either glaucoma, paediatric cataract, external disease or disorders related to the ocular adnexa requiring oculoplastic treatment were reviewed. Records recalled from the Cyber-Sight electronic archives included: medical history, images of clinical findings, partner diagnosis, partner treatment plan, mentor diagnosis, and mentor treatment plan. Partners' diagnosis and treatment plans were compared with those of the mentors. Based on results of prior studies, mentor opinions were those considered valid (Helveston et al., 2001).

A total of 135 cases were reviewed; 70 external disease, 42 oculoplastics, 16 glaucoma and seven paediatric cataract. The partner's diagnosis agreed with that of the mentor in 81% of glaucoma cases, 86% of paediatric cataract cases, 76% of external disease cases and 86% of oculoplastic cases. The local ophthalmologists were considered to have suggested the correct treatment plan in 56% of glaucoma cases, 71% of paediatric cataract cases, 70% of external disease cases, and 60% of oculoplastic cases. Mentors provided additional comments and suggestions for further study in more than three-quarters of the cases.

If one considers that the mentors are correct in each case, they offered a different diagnosis in 18% of cases and in terms of treatment, the mentors offered an alternate plan in more than a quarter of cases. However, it is still to be determined whether this type of consultation changes the outcome of treatment.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.